The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review.

ABSTRACT: Rare cancers and other rare nonmalignant tumors comprise 25% of all cancer diagnoses and account for 25% of all cancer deaths. They are difficult to study due to many factors, including infrequent occurrence, lack of a universal infrastructure for data and/or tissue collection, and a paucity of disease models to test potential treatments. For each individual rare cancer, the limited number of diagnosed cases makes it difficult to recruit sufficient patients for clinical studies, and rare cancer research studies are often siloed. As a result, progress has been slow for many of these cancers. While rare cancer research efforts have increased over time, the breadth of the research landscape is not known. A recent literature search revealed a sharp increase in rare tumor, and rare cancer publi

SUBMITTER: Vivelo C 

PROVIDER: S-EPMC10836296 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature